title: Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: clinical meaning and value.
abstract: Pericardial involvement (PI) in acute myocardial infarction (AMI) is a complication usually considered benign and has therefore received less attention than those more severe. It may be easily missed because it presents few symptoms and signs, which in turn may be confused with those of AMI. Its pathophysiology, diagnosis, and pitfalls are discussed. The GISSI-1 trial revealed a marked reduction of PI in the group treated with thrombolysis. This unexpected finding was later confirmed by the GISSI-2 trial and by other studies, drawing attention to its meaning. Data from the GISSI as well as from other studies have been reviewed and seem to indicate that PI is associated with larger AMIs and with a significant increase in 6- and 12-month mortality. This may be attributed to the consequences of late remodeling of a large infarction. These findings lead to the conclusion that PI should be granted more attention, and that it might identify patients with a poorer long-term outcome.
authors.affiliation: Ospedale Civile di Caserta, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Correale
authors.forename: A P
authors.initials: AP
authors.lastname: Maggioni
authors.forename: S
authors.initials: S
authors.lastname: Romano
authors.forename: V
authors.initials: V
authors.lastname: Ricciardiello
authors.forename: R
authors.initials: R
authors.lastname: Battista
authors.forename: E
authors.initials: E
authors.lastname: Santoro
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D010493:Pericarditis / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D015912:Thrombolytic Therapy
chemical_list: D005343:Fibrinolytic Agents